Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › AARTIDRUGS

AARTIDRUGS

Aarti Drugs Limited
Micro-capPharma ↗

What the six lenses say about AARTIDRUGS — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹423.0
2026-09-08
VWAP · 1Y anchor
₹420
+0.6% from VWAP
P/E · TTM
19.8×
TTM EPS ₹21.4
52-week range
50%
position low→high
RSI(14)
53
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How AARTIDRUGS’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
7.0
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Micro-cap cohortDRaw
TechnicalD995›

The actual numbers

Price vs VWAP (1y)+0.6%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+4.7%
Price vs 50-EMA+3.1%
RSI(14)53
RS vs Nifty 500 · 3M+11.1%
RS vs sector · 3M+5.1%
52-week range50%
Volume vs 30d avg0.30×
Volume vs 60d avg0.30×
ATR(14) · volatility14.9
Bollinger width · vol contraction0.072
FundamentalD436›

The actual numbers

Return on equity (ROE)12.6%
Operating margin9.5%
Net margin7.6%
Revenue growth · YoY+7.5%
EPS growth · YoY+16.1%
Debt / equity0.37×

Full 8-quarter history in the financials table below.

ValuationD751›

The actual numbers

P/E (TTM)19.8×
TTM EPS₹21.4
52-week range50%
CatalystD640›

The actual numbers

Earnings & momentum43
Capital actions19
Governance74

Every filing in the corporate-announcements panel below.

FlowD550›

The actual numbers

Promoter holding55.0%
Delivery · 30d avg49.6%
Up/down-day asymmetry-0.5pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Micro-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D9 + D5 ) ÷ 2 = 7.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
91
Conviction score 91/100 · avg-decile strength 7.0/10
Conviction score91/100›
TechnicalD9›
FundamentalD4›
ValuationD7›
CatalystD6›
FlowD5›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
-1.5pp
+4.0pp
+6.4pp
+12.7pp
+21.2pp
-7.3pp
Nifty 500
Broad-market baseline
-1.6pp
+4.0pp
+5.4pp
+11.1pp
+15.5pp
-12.6pp
Sector
Own-sector index
—
—
+2.5pp
+5.1pp
+2.3pp
-33.4pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

AARTIDRUGS daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
423.00-8.65

Relative strength

RS vs baseline · rebased to 100

AARTIDRUGS ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
78.84-1.27

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)555598557677591653602720
↳ change QoQ—+7.7%-7.0%+21.6%-12.7%+10.5%-7.8%+19.6%
EBITDA (₹cr)6669749374845596
EBITDA margin11.9%11.5%13.2%13.7%12.5%12.9%9.1%13.3%
PAT (₹cr)3335376354454155
↳ change QoQ—+5.1%+6.1%+69.9%-14.3%-16.7%-8.9%+34.1%
Net margin6.0%5.8%6.7%9.3%9.1%6.9%6.8%7.6%
EPS (₹)3.623.834.066.895.914.964.446.05
D/E0.00———————
YoY growth · Mar '26Revenue +6.4% YoYPAT -12.7% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 2 Sep '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 27 Aug '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 14 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Aug '26
    LOWgovernance
    Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 7 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 4 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 3 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 1 Aug '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 1 Aug '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 1 Aug '26
    LOWgovernance
    Action(s) taken or orders passed
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 31 Jul '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 31 Jul '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 31 Jul '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 29 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 18 Jul '26
    LOWgovernance
    Action(s) taken or orders passed
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds AARTIDRUGS

Mutual funds holding AARTIDRUGS (3)

FundWeightAUM ₹crGrade
DSP Small Cap Reg Gr1.34%20,221
ICICI Pru Pharma Healthcare Diag Gr1.16%6,803
DSP Healthcare Fund Reg Gr0.99%3,639

ETFs holding AARTIDRUGS (0)

No tracked ETF holds AARTIDRUGS ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma